Company news

PegBio Co., Ltd. news

Latest news releases, newest first.

View company

Voluntary announcement successful inclusion of the group's core product paidakang (visepegenatide injection) into the 2026 NRDL

November 15, 2026

Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 26, 2026

November 11, 2026

Notice of the 2026 first extraordinary general meeting

November 11, 2026

(1) Proposed removal of auditor (2) proposed appointment of auditor (3) proposed change in use of proceeds from the global offering and (4) notice of the 2026 first extraordinary general meeting

November 11, 2026

Next Day Disclosure Return

November 10, 2026

Completion of placing of new h shares under general mandate

November 10, 2026

Cancellation of extraordinary general meeting and cancellation of book closure period

November 6, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 4, 2026

Placing of new h shares under general mandate

November 2, 2026

Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 12, 2026

October 23, 2026

Notice of the 2026 first extraordinary general meeting

October 23, 2026

(1) Proposed removal of auditor (2) proposed appointment of auditor (3) proposed change in use of proceeds from the global offering and (4) notice of the 2026 first extraordinary general meeting

October 23, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 7, 2026

2026 Interim Report

September 23, 2026

Change in use of proceeds from the global offering

September 18, 2026

Proposed change of auditor

September 18, 2026

Voluntary announcement core product Visepegenatide injection passed the preliminary review in accordance with the 2026 national reimbursement drug list adjustment

June 29, 2026

Next Day Disclosure Return

June 26, 2026

List of directors and their roles and functions

June 24, 2026